(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

Humira (adalimumab) is used to treat several autoimmune conditions. The drug typically stays in your system for a few months after your final dose. This article explains how long Humira may remain in ...

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

Even through an onslaught of biosimilar launches that began early last year, AbbVie’s big-selling Humira has been able to retain most of its lucrative market. Still, though, the drug’s star power is ...

Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

AbbVie’s Humira sales slipped last year as the Big Pharma dealt with the first real generic erosion of its immunology megablockbuster, but its backup meds will be more than enough to not just shore up ...

Evio Pharmacy Solutions, the for-profit pharmacy solutions company formed by five Blue Cross & Blue Shield licensees, said today it has entered a unique direct-purchase deal for a cheaper version of ...

Oct 20 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a head-to-head . AbbVie has been ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique legal challenge, the Dutch Pharmaceutical ...